<unk>  is a nucleoside metabolic inhibitor that is FDA approved for the treatment of advanced ovarian cancer, metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, non-small cell lung cancer, and pancreatic cancer.   Common adverse reactions include nausea/vomiting, anemia, hepatic transaminitis, neutropenia, increased alkaline phosphatase, proteinuria, fever, hematuria, rash, thrombocytopenia, dyspnea, and peripheral edema.
Gemcitabine
Ifosfamide
Zorubicin
Mafosfamide
Fluorouracil 
Idoxuridine
Semustine
Carboplatin